Institutional Ownership Percentage: 8/19/19- 60.98% 8/14/19 - 60.15% Shares Purchased this month by Institutions: 19 Million . Q2-19 Financial Results. Product revenue, net in the second quarter 2019 was $28.8 million

7572

Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities.

CPRX Stock Price and Chart — NASDAQ:CPRX — TradingView — … Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile CPRX stock: Catalyst Pharmaceuticals Inc Catalyst Pharmaceuticals Inc's stock rating is based on fundamental analysis. Don't miss CPRX stock next rating changes Earnings Whisper Number for CPRX: Catalyst Pharm Catalyst Pharm (CPRX) reports earnings on 8/10/2020. Shares are down 8.5% since reporting last quarter. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings.

  1. Td ameritrade内部转账费
  2. Amscot折扣股票经纪

CPRX Stock Quote. Following its IPO, Catalyst Pharmaceuticals share price dropped. Investors didn’t see prices rise again for almost a half decade. The share prices again saw highs in the $5 range in 2015, but within a year the stock plummeted to under a dollar. CPRX Stock Price & Charts | Catalyst Pharmaceuticals In depth view into CPRX (Catalyst Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. Catalyst Pharmaceuticals, Inc. (CPRX) Blog Posts | Seeking ...

Catalyst Pharmaceuticals (CPRX) Stock Climbs On Cancelled ...

CPRX Stock Price & Charts | Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (US:CPRX) has 299 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 65,865,448 shares. CPRX Stock | Message Board | Catalyst Pharmaceuticals Inc ... CPRX Stock Message Board for Investors. Catalyst Pharmaceuticals Inc. Stock Price, News and Company Updates. Message Board Total Posts: 61

Current Technical Analysis and interactive chart for $CPRX stock / shares. See the current CPRX Ideas on StockTwits · CPRX Tweets on Twitter. Indicators 

Cprx stocktwits

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3.

Cprx stocktwits




Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Pre ...

(NasdaqCM:CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases,  Yesterday, a stock I've been following for a while, CPRX (Catalyst Pharmaceuticals), was taken to the woodshed. On May 6, the stock closed at $6.11, its highest 


英国S&S贸易公司

(NasdaqCM:CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, 

CPRX: Catalyst Pharmaceuticals Inc - Zacks Investment Research CPRX: Catalyst Pharmaceuticals Inc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Catalyst Pharmaceuticals Inc from Zacks Investment Research Catalyst Pharmaceuticals, Inc. (CPRX) stock price, quote ... Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock? Catalyst Catalystpharma.com - A Singular Mission Please follow @CatalystPharma on Facebook and Twitter for updates. Now there’s an FDA-approved, first-line treatment for adults with LEMS. 1,2 Learn More. INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in … CPRX Institutional Ownership - Catalyst Pharmaceuticals ...